The LITO lab consists in 2 research groups with tight interactions:

  • The first group is the Biomarkers for Phenotype Imaging group and is dedicated to the design and evaluation of innovative radiotracers for molecular imaging using Positron Emission Tomography (PET) to target molecular mechanisms key to cancer development. The goal of this group is twofold: first, better understand the mechanisms underlying cancer development and response or resistance to treatment, second optimize patient management through the identification of imaging phenotype assisting personalized medicine.
  • The second group is the Integrated Radiomics for Precision Medicine group. This group takes davantage of PET biomarkers, but also biomarkers from Magnetic Resonance Imaging (MRI) and computer tomography (CT) and combines these biomarkers with other types of biomarkers (clinical, pathological, omics, from liquid biopsies) to profile the cancer disease for prognostic or predictive purpose. The models are also developed in such a way that they contribute to a better understanding of cancer-related processes.

The members of LITO (about 30 researchers, physicists, engineers, MDs, PharmDs, technologists, and PhD students) are working on the 3 sites of Institut Curie: at the research Center (Orsay) and in the Imaging and Pharmacology Departments of the Hospital (Saint Cloud and Paris).